T1	Participants 79 139	after autologous blood stem cell transplantation in children
T2	Participants 188 229	Japanese Cooperative Study Group of PBSCT
T3	Participants 270 408	74 children who were scheduled to undergo high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (PBSCT)
T4	Participants 567 601	hematopoietic recovery after PBSCT
T5	Participants 603 734	The diagnosis included acute lymphoblastic leukemia (ALL) (n = 27), neuroblastoma (n = 29), and miscellaneous solid tumors (n = 18)
T6	Participants 736 972	Eligibility criteria included (1) primary PBSCT, (2) chemotherapy-responsive disease, and (3) collected cell number >1 x 10(5) colony-forming unit-granulocyte-macrophage (CFU-GM)/kg and >1 x 10(6) CD34(+) cells/kg patient's body weight.
T7	Participants 1008 1159	11 patients were excluded due to disease progression before PBSCT (n = 6) or a low number of harvested cells (n = 5), leaving 63 patients for analysis;
T8	Participants 1703 1829	Five patients (two in the treatment group and three in the control group) were subsequently removed due to protocol violations
T9	Participants 3342 3414	routine application of costly G-CSF therapy in children undergoing PBSCT
